$12.95
0.62%
NYSE, Dec 26, 10:00 pm CET
ISIN
US03168L1052
Symbol
AMRX

Amneal Pharmaceuticals, Inc. Class A Stock price

$12.95
+0.43 3.43% 1M
+4.82 59.29% 6M
+5.03 63.51% YTD
+5.10 64.97% 1Y
+10.75 488.64% 3Y
+8.47 189.06% 5Y
-29.81 69.71% 10Y
+8.28 177.30% 20Y
NYSE, Closing price Fri, Dec 26 2025
+0.08 0.62%
ISIN
US03168L1052
Symbol
AMRX
Industry

Key metrics

Basic
Market capitalization
$4.1b
Enterprise Value
$6.5b
Net debt
$2.4b
Cash
$201.3m
Shares outstanding
314.3m
Valuation (TTM | estimate)
P/E
647.5 | 15.9
P/S
1.4 | 1.3
EV/Sales
2.2 | 2.1
EV/FCF
27.5
P/B
negative
Financial Health
Equity Ratio
-3.1%
Return on Equity
107.0%
ROCE
13.2%
ROIC
13.2%
Debt/Equity
-24.1
Financials (TTM | estimate)
Revenue
$2.9b | $3.1b
EBITDA
$602.0m | $691.5m
EBIT
$361.5m | $572.7m
Net Income
$5.9m | $256.2m
Free Cash Flow
$236.5m
Growth (TTM | estimate)
Revenue
45.2% | 10.0%
EBITDA
30.8% | 18.3%
EBIT
55.0% | 64.4%
Net Income
106.4% | 319.2%
Free Cash Flow
3.2%
Margin (TTM | estimate)
Gross
36.8%
EBITDA
20.5% | 22.5%
EBIT
12.3%
Net
0.2% | 8.3%
Free Cash Flow
8.1%
More
EPS
$0.0
FCF per Share
$0.8
Short interest
2.6%
Employees
8k
Rev per Employee
$340.0k
Show more

Is Amneal Pharmaceuticals, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Amneal Pharmaceuticals, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Amneal Pharmaceuticals, Inc. Class A forecast:

Buy
90%
Hold
10%

Financial data from Amneal Pharmaceuticals, Inc. Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2,935 2,935
45% 45%
100%
- Direct Costs 1,856 1,856
41% 41%
63%
1,079 1,079
52% 52%
37%
- Selling and Administrative Expenses 517 517
49% 49%
18%
- Research and Development Expense 206 206
44% 44%
7%
602 602
31% 31%
21%
- Depreciation and Amortization 240 240
6% 6%
8%
EBIT (Operating Income) EBIT 361 361
55% 55%
12%
Net Profit 5.90 5.90
106% 106%
0%

In millions USD.

Don't miss a Thing! We will send you all news about Amneal Pharmaceuticals, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amneal Pharmaceuticals, Inc. Class A Stock News

Neutral
GlobeNewsWire
7 days ago
BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced that the U.S. Food and Drug Administration (FDA) has approved its Biologics Licensing Applications (BLAs) for Boncresa™ (denosumab-mobz), a biosimilar referencin...
Positive
Seeking Alpha
11 days ago
Today's article presents why Amneal should get my prior buy rating from September reaffirmed. Although some technical signals support a hold rather than bullishness, fundamental analysis shows several upside drivers, including a robust and growing drug portfolio. Despite negative equity, the company also raised its operating cash flow guidance for FY25.
Neutral
GlobeNewsWire
20 days ago
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's epinephrine injection USP, 1 mg/mL (1 mL), in single-dose vials and 1 mg/mL (30 mL) multi-dose vials. This medicine is a critical therapy utilized by hospitals, emergency departmen...
More Amneal Pharmaceuticals, Inc. Class A News

Company Profile

Amneal Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development, manufacture, market and distribution of generic pharmaceutical products. It operates through the Generics and Specialty segments. The Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermals. The Specialty segment provides proprietary medicines to the U.S. market. The company was founded by Chintu Patel and Chirag Patel in 2002 and is headquartered in Bridgewater, NJ.

Head office United States
CEO Chintu Patel
Employees 8,300
Founded 2002
Website amneal.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today